BioWorld

Dec. 1, 2003

Praecis Gets First Approval: Plenaxis In Prostate Cancer

Prostate cancer patients gained a new treatment option on Nov. 25 as the FDA approved Plenaxis, a drug fully developed by Praecis Pharmaceuticals Inc. (BioWorld Today) Read More

Genentech's Avastin Misses Primary Endpoint In Phase II

Largest Stroke Trials Worldwide Compare Oral Anti-Ischemic Drugs With Current Warfarin Prevention

Medicare Bill To White House; Most Applaud New Regulations

Holiday Notice

Chronogen Series B Raises C$17M For Longevity Work

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...